Total Payments
$1.0M
2024 Payments
$57,064
Companies
48
Transactions
2,038
Medicare Patients
21,968
Medicare Billing
$1.8M
Payment Breakdown by Category
Other$684,753 (67.6%)
Consulting$150,849 (14.9%)
Research$95,370 (9.4%)
Food & Beverage$42,359 (4.2%)
Travel$37,941 (3.7%)
Education$1,445 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $589,786 | 317 | 58.2% |
| Consulting Fee | $150,849 | 49 | 14.9% |
| Unspecified | $95,370 | 17 | 9.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $50,600 | 16 | 5.0% |
| Food and Beverage | $42,359 | 1,477 | 4.2% |
| Travel and Lodging | $37,941 | 106 | 3.7% |
| Honoraria | $36,368 | 15 | 3.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,000 | 5 | 0.8% |
| Education | $1,445 | 36 | 0.1% |
Payments by Type
General
$917,348
2,021 transactions
Research
$95,370
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $207,213 | 348 | $0 (2024) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $134,188 | 169 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $110,315 | 192 | $0 (2024) |
| Galderma Laboratories, L.P. | $83,240 | 211 | $0 (2024) |
| Lilly USA, LLC | $79,738 | 132 | $0 (2024) |
| PFIZER INC. | $65,417 | 93 | $0 (2024) |
| Bausch Health US, LLC | $58,300 | 5 | $0 (2019) |
| Dermavant Sciences, Inc. | $38,520 | 43 | $0 (2024) |
| Incyte Corporation | $36,166 | 88 | $0 (2024) |
| Allergan, Inc. | $36,033 | 50 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $57,064 | 185 | ABBVIE INC. ($18,392) |
| 2023 | $110,470 | 261 | Dermavant Sciences, Inc. ($26,354) |
| 2022 | $78,795 | 256 | ABBVIE INC. ($19,132) |
| 2021 | $94,694 | 247 | AbbVie Inc. ($36,748) |
| 2020 | $89,390 | 168 | AbbVie Inc. ($32,129) |
| 2019 | $218,825 | 308 | AbbVie, Inc. ($65,947) |
| 2018 | $225,087 | 348 | Bausch Health US, LLC ($56,800) |
| 2017 | $138,394 | 265 | Novartis Pharmaceuticals Corporation ($37,429) |
All Payment Transactions
2,038 individual payment records from CMS Open Payments — Page 1 of 82
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $3.43 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $29.50 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $5.04 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Lilly USA, LLC | — | Food and Beverage | Cash or cash equivalent | $122.31 | General |
| 12/10/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $80.64 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $31.76 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $8.46 | General |
| Category: Dermatology | ||||||
| 11/27/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.29 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $30.11 | General |
| Category: Immunology | ||||||
| 11/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $29.50 | General |
| Category: Dermatology | ||||||
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.64 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $9.52 | General |
| Category: Dermatology | ||||||
| 11/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $45.61 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $7.51 | General |
| Category: Immunology | ||||||
| 11/08/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $37.52 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $31.59 | General |
| Category: Immunology | ||||||
| 11/08/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $18.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/02/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $19.52 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $58,300 | 5 |
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTI CENTER STUDY IN PARALLEL GROUPS TO ASSESS THE EFFICACY AND SAFETY OF CJM112 IN PATIENTS WITH MODERATE TO SEVERE INFLAMMATORY ACNE | NOVARTIS PHARMACEUTICALS CORPORATION | $17,294 | 1 |
| EFFICACY AND SAFETY OF ADAPALENE 0.35BENZOYL PEROXIDE 2.5 GEL PLUS DOXYCYCLINE IN SEVERE INFLAMMATORY ACNE NON-NODULOCYSTIC SUBJECTS | Galderma Laboratories, L.P. | $8,840 | 4 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB DOSING REGIMENS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $3,120 | 1 |
| A Prospective Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis who Achieve Complete Clearance on Biologics Brodalumab | AstraZeneca UK Limited | $2,800 | 1 |
| EFFICACY AND SAFETY OF INGENOL MEBUTATE GEL FOR ACTINIC KERATOSIS APPLIED ON LARGE AREA ON FACE, SCALP OR CHEST | LEO Pharma AS | $1,996 | 1 |
| CC-10004-PSOR-012 | Celgene Corporation | $1,011 | 1 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND STUDY OF SECUKINUMAB 300 MG TO DEMONSTRATE EFFICACY AS ASSESSED BY PSORIASIS AREA AND SEVERITY INDEX AND INVESTIGATORS GLOBAL ASSESSMENT AFTER 12 WEEKS OF TREATMENT, COMPARED TO USTEKINUMAB AND TO ASSESS LONG TERM SAFETY TOLERABILITY AND EFFICACY IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS CLARITY | NOVARTIS PHARMACEUTICALS CORPORATION | $837.90 | 1 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $685.89 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $485.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 6,014 | 11,295 | $2.0M | $552,398 |
| 2022 | 25 | 5,368 | 9,917 | $825,997 | $432,746 |
| 2021 | 28 | 5,448 | 10,066 | $701,215 | $427,600 |
| 2020 | 25 | 5,138 | 9,577 | $653,270 | $409,375 |
Total Patients
21,968
Total Services
40,855
Medicare Billing
$1.8M
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,426 | 2,508 | $543,883 | $158,757 | 29.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 646 | 769 | $206,261 | $53,883 | 26.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 950 | 1,356 | $224,065 | $53,312 | 23.8% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 119 | 130 | $101,421 | $31,562 | 31.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 293 | 353 | $103,387 | $29,688 | 28.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 328 | 488 | $66,280 | $22,228 | 33.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 746 | 3,940 | $66,665 | $21,825 | 32.7% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 56 | 61 | $47,653 | $17,666 | 37.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 243 | 243 | $64,419 | $17,368 | 27.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 155 | 169 | $56,483 | $15,801 | 28.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 254 | 349 | $46,989 | $14,550 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 119 | 155 | $47,498 | $13,660 | 28.8% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 55 | 55 | $42,197 | $13,548 | 32.1% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 59 | 70 | $33,757 | $10,425 | 30.9% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 71 | 94 | $58,199 | $10,107 | 17.4% |
| 12042 | Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm | Office | 2023 | 32 | 37 | $28,887 | $9,180 | 31.8% |
| 12052 | Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | Office | 2023 | 32 | 32 | $25,354 | $8,239 | 32.5% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 78 | 83 | $25,430 | $7,487 | 29.4% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 41 | 50 | $22,364 | $6,281 | 28.1% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 42 | 49 | $34,155 | $6,004 | 17.6% |
| 12034 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 7.6-12.5 cm | Office | 2023 | 18 | 22 | $18,523 | $5,996 | 32.4% |
| 11622 | Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 35 | 40 | $25,496 | $4,451 | 17.5% |
| 11642 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 35 | 37 | $24,880 | $4,361 | 17.5% |
| 69100 | Biopsy of ear | Office | 2023 | 61 | 70 | $17,513 | $3,862 | 22.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 24 | 26 | $10,863 | $3,525 | 32.4% |
About Dr. Emil Tanghetti, M.D
Dr. Emil Tanghetti, M.D is a Dermatology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043250145.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emil Tanghetti, M.D has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $57,064 received in 2024. These payments were reported across 2,038 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($589,786).
As a Medicare-enrolled provider, Tanghetti has provided services to 21,968 Medicare beneficiaries, totaling 40,855 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Sacramento, CA
- Active Since 06/07/2006
- Last Updated 12/18/2013
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1043250145
Products in Payments
- COSENTYX (Biological) $92,741
- SKYRIZI (Biological) $69,905
- TALTZ (Drug) $64,535
- EPIDUO FORTE (Drug) $54,438
- EUCRISA (Drug) $53,734
- HUMIRA (Biological) $44,288
- ARAZLO (Drug) $40,967
- VTAMA (Drug) $38,520
- OPZELURA (Drug) $36,166
- Humira (Biological) $34,990
- Skyrizi (Biological) $30,202
- DUOBRII (Drug) $28,229
- SILIQ (Drug) $24,552
- SOOLANTRA (Drug) $24,324
- QBREXZA (Drug) $18,458
- CJM112 (Drug) $17,294
- RHOFADE (Drug) $16,882
- ONEXTON (Drug) $14,064
- RINVOQ (Biological) $11,916
- CIBINQO (Drug) $11,613
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Sacramento
Dr. Raja Sivamani, M.d., M.s., A.h.e, M.D., M.S., A.H.E
Dermatology — Payments: $1.3M
Dermatology $1.3M
Jacqueline Calkin, M.d, M.D
Dermatology — Payments: $130,291
Dermatology $130,291
Dr. Emanual Maverakis, M.d, M.D
Dermatology — Payments: $52,284
Dermatology $52,284
Alison Boudreaux, M.d, M.D
Dermatology — Payments: $46,728
Dermatology $46,728
Mirza Alikhan, Md, MD
Dermatology — Payments: $30,111
Dermatology $30,111
Jennifer Ornelas
Dermatology — Payments: $28,781
Dermatology $28,781